Following a $40 million venture round in January, Seattle-based Alder Biopharmaceuticals has plans to ramp up its antibody work and will hire a number of new researchers. In a move to boost its staff from 34 to about 50, the biotech is searching for workers skilled at antibody manufacturing and clinical development. That's all good news for the Seattle area, where the biotech scene has been the center of more downsizing than upsizing in recent years.
- read the report [1] in the Seattle Times
Related Articles:
Alder lands $40M in third round [2]
Alder pockets $16M in VC [3]
Links:
[1] http://seattletimes.nwsource.com/html/biotech/2008013843_alder24.html
[2] http://www.fiercebiotech.com/story/alder-lands-40m-third-round/2008-01-11
[3] http://www.fiercebiotech.com/story/spotlight-alder-pockets-16m-in-vc/2006-07-11